{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:33:50Z","timestamp":1789947230372,"version":"4.0.1"},"reference-count":100,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,5,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Myeloproliferative neoplasms (MPNs) include essential thrombocythemia, polycythemia vera (PV), and primary myelofibrosis (MF). Phenotype-driver mutations of JAK2, CALR, and MPL genes are present in MPNs and can be variably combined with additional mutations. Driver mutations entail a constitutive activation of the JAK2\/STAT pathway, the key signaling cascade in MPNs. Among JAK2 inhibitors (JAKis), ruxolitinib (RUX) has been approved for the treatment of intermediate and high-risk MF and for PV inadequately controlled by or intolerant of hydroxyurea. Other JAKis, such as fedratinib and pacritinib, proved to be useful in MF. The primary end points in MF trials were spleen volume response (SVR) and symptom response, whereas in PV trials they were hematocrit control with or without spleen response. In advanced MF, RUX achieved a long lasting SVR of &gt;35% in \u223c60% of patients, establishing a new benchmark for MF treatment. RUX efficacy in early MF is also remarkable and toxicity is mild. In PV, RUX achieved hematocrit control in \u223c60% of cases and SVR in 40%. Symptom relief was evident in both conditions. In the long-term, however, many MF patients lose their SVR. Indeed, the definition of RUX failure and the design of new trials in this setting are unmet needs. Decrease of hemoglobin\/platelet levels and increased infection rates are the most common side effects of RUX, and nonmelanoma skin tumors need to be monitored while on treatment. In conclusion, the introduction of JAKis raises the bar of treatment goals in MF and PV.<\/jats:p>","DOI":"10.1182\/blood-2018-01-791491","type":"journal-article","created":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T15:50:14Z","timestamp":1523548214000},"page":"2426-2435","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":52,"title":["The role of JAK2 inhibitors in MPNs 7 years after approval"],"prefix":"10.1182","volume":"131","author":[{"given":"Francesco","family":"Passamonti","sequence":"first","affiliation":[{"name":"Dipartimento di Medicina e Chirurgia, University of Insubria, Varese, Italy; and"},{"name":"Hematology, Dipartimento di Medicina Specialistica, ASST Settelaghi Varese, Ospedale di Circolo, Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Maffioli","sequence":"additional","affiliation":[{"name":"Hematology, Dipartimento di Medicina Specialistica, ASST Settelaghi Varese, Ospedale di Circolo, Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019111904555590100_B1","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/asheducation-2016.1.534","article-title":"Update from the latest WHO classification of MPNs: a user\u2019s manual","volume":"2016","author":"Passamonti","year":"2016","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"5","key":"2019111904555590100_B2","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/cncr.21297","article-title":"Leukemic transformation of polycythemia vera: a single center study of 23 patients","volume":"104","author":"Passamonti","year":"2005","journal-title":"Cancer"},{"issue":"4","key":"2019111904555590100_B3","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/leu.2016.351","article-title":"Driver mutations\u2019 effect in secondary myelofibrosis: an international multicenter study based on 781 patients","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"issue":"9","key":"2019111904555590100_B4","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"issue":"10","key":"2019111904555590100_B5","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","article-title":"Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations","volume":"117","author":"Passamonti","year":"2011","journal-title":"Blood"},{"issue":"21","key":"2019111904555590100_B6","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1182\/blood-2013-02-486050","article-title":"Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms","volume":"121","author":"Rumi","year":"2013","journal-title":"Blood"},{"issue":"25","key":"2019111904555590100_B7","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111904555590100_B8","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","article-title":"Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells","volume":"17","author":"Mullally","year":"2010","journal-title":"Cancer Cell"},{"issue":"4","key":"2019111904555590100_B9","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/2159-8290.CD-15-1434","article-title":"Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation","volume":"6","author":"Elf","year":"2016","journal-title":"Cancer Discov"},{"issue":"22","key":"2019111904555590100_B10","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood"},{"issue":"15","key":"2019111904555590100_B11","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quint\u00e1s-Cardama","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2019111904555590100_B12","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1056\/NEJMc1400499","article-title":"JAK inhibitor in CALR-mutant myelofibrosis","volume":"370","author":"Passamonti","year":"2014","journal-title":"N Engl J Med"},{"issue":"14","key":"2019111904555590100_B13","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1182\/blood-2013-11-536557","article-title":"Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study","volume":"123","author":"Guglielmelli","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111904555590100_B14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3324\/haematol.2008.001271","article-title":"Clinical relevance of JAK2 (V617F) mutant allele burden","volume":"94","author":"Passamonti","year":"2009","journal-title":"Haematologica"},{"issue":"7","key":"2019111904555590100_B15","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood-2007-11-121434","article-title":"A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis","volume":"111","author":"Passamonti","year":"2008","journal-title":"Blood"},{"issue":"10","key":"2019111904555590100_B16","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2019111904555590100_B17","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2015.277","article-title":"Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms","volume":"30","author":"Pietra","year":"2016","journal-title":"Leukemia"},{"issue":"26","key":"2019111904555590100_B18","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"2019111904555590100_B19","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"issue":"14","key":"2019111904555590100_B20","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111904555590100_B21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3324\/haematol.2014.113845","article-title":"Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms","volume":"102","author":"Grinfeld","year":"2017","journal-title":"Haematologica"},{"issue":"9","key":"2019111904555590100_B22","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"issue":"9","key":"2019111904555590100_B23","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.76","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients","volume":"28","author":"Guglielmelli","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"2019111904555590100_B24","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2015-03-633404","article-title":"Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib","volume":"126","author":"Patel","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2019111904555590100_B25","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3324\/haematol.2010.034488","article-title":"The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms","volume":"96","author":"Olcaydu","year":"2011","journal-title":"Haematologica"},{"issue":"9","key":"2019111904555590100_B26","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111904555590100_B27","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111904555590100_B28","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"issue":"7","key":"2019111904555590100_B29","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol"},{"issue":"5","key":"2019111904555590100_B30","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol"},{"key":"2019111904555590100_B31","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial [published online ahead of print 8 March 2018]","author":"Mascarenhas","journal-title":"JAMA Oncol"},{"issue":"34","key":"2019111904555590100_B32","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor-na\u00efve patients with myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2019111904555590100_B33","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1200\/JCO.2017.35.15_suppl.7001","article-title":"Phase 3 randomized trial of momelotinib (MMB) versus best available therapy (BAT) in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX)","volume":"35","author":"Harrison","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111904555590100_B34","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/leu.2016.215","article-title":"A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis","volume":"31","author":"Verstovsek","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"2019111904555590100_B35","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111904555590100_B36","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol"},{"issue":"15","key":"2019111904555590100_B37","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood-2017-02-765032","article-title":"Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results","volume":"130","author":"Verstovsek","year":"2017","journal-title":"Blood"},{"issue":"17","key":"2019111904555590100_B38","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1182\/blood-2017-05-785790","article-title":"Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide","volume":"130","author":"Harrison","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2019111904555590100_B39","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3324\/haematol.2016.143644","article-title":"Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial","volume":"101","author":"Verstovsek","year":"2016","journal-title":"Haematologica"},{"key":"2019111904555590100_B40","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.leukres.2017.06.001","article-title":"Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis","volume":"59","author":"Masarova","year":"2017","journal-title":"Leuk Res"},{"key":"2019111904555590100_B41","article-title":"A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea","author":"Verstovsek","year":"2013","journal-title":"Cancer"},{"issue":"4","key":"2019111904555590100_B42","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00277-017-3225-1","article-title":"Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies","volume":"97","author":"Kiladjian","year":"2018","journal-title":"Ann Hematol"},{"issue":"1","key":"2019111904555590100_B43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2019111904555590100_B44","first-page":"322","article-title":"Results from the 208-week (4-Year) follow-up of RESPONSE trial, a phase 3 study comparing ruxolitinib (Rux) with best available therapy (BAT) for the treatment of polycythemia vera (PV) [abstract]","volume":"130","author":"Kiladjian","year":"2017","journal-title":"Blood"},{"issue":"20","key":"2019111904555590100_B45","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","article-title":"Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference","volume":"113","author":"Barosi","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2019111904555590100_B46","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3324\/haematol.2016.152769","article-title":"Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea","volume":"102","author":"Alvarez-Larr\u00e1n","year":"2017","journal-title":"Haematologica"},{"issue":"6","key":"2019111904555590100_B47","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.3324\/haematol.2017.165126","article-title":"No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials","volume":"102","author":"Barbui","year":"2017","journal-title":"Haematologica"},{"issue":"5","key":"2019111904555590100_B48","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/bjh.13886","article-title":"Frequency and prognostic value of resistance\/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera","volume":"172","author":"Alvarez-Larr\u00e1n","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111904555590100_B49","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/blood-2015-04-638593","article-title":"White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study","volume":"126","author":"Barbui","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2019111904555590100_B50","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/cncr.28441","article-title":"A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea","volume":"120","author":"Verstovsek","year":"2014","journal-title":"Cancer"},{"key":"2019111904555590100_B51","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet [published online ahead of print 27 February 2018]","author":"Barbui","journal-title":"Leukemia"},{"issue":"10","key":"2019111904555590100_B52","first-page":"1011","article-title":"Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients","volume":"85","author":"Passamonti","year":"2000","journal-title":"Haematologica"},{"issue":"1","key":"2019111904555590100_B53","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","article-title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"9","key":"2019111904555590100_B54","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","article-title":"A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis","volume":"100","author":"Vannucchi","year":"2015","journal-title":"Haematologica"},{"issue":"9","key":"2019111904555590100_B55","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2019111904555590100_B56","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"issue":"10","key":"2019111904555590100_B57","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111904555590100_B58","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2019111904555590100_B59","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111904555590100_B60","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3324\/haematol.2016.151126","article-title":"Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis","volume":"102","author":"Mascarenhas","year":"2017","journal-title":"Haematologica"},{"issue":"23","key":"2019111904555590100_B61","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/blood.V126.23.56.56","article-title":"PRM-151 in myelofibrosis: durable efficacy and safety at 72 weeks","volume":"126","author":"Verstovsek","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2019111904555590100_B62","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111904555590100_B63","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2011-11-393819","article-title":"Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome","volume":"119","author":"Barbui","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2019111904555590100_B64","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/leu.2016.323","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"31","author":"Harrison","year":"2017","journal-title":"Leukemia"},{"issue":"23","key":"2019111904555590100_B65","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.V126.23.59.59","article-title":"Long-term efficacy and safety in COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for the treatment of myelofibrosis: 5-year final study results","volume":"126","author":"Harrison","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2019111904555590100_B66","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00277-017-2994-x","article-title":"Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study","volume":"96","author":"Vannucchi","year":"2017","journal-title":"Ann Hematol"},{"issue":"10","key":"2019111904555590100_B67","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1056\/NEJMoa1503479","article-title":"Telomerase inhibitor imetelstat in patients with essential thrombocythemia","volume":"373","author":"Baerlocher","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111904555590100_B68","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/blood-2012-02-414631","article-title":"Long-term outcomes of 107 patients with myelofibrosis receiving JAK1\/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls","volume":"120","author":"Verstovsek","year":"2012","journal-title":"Blood"},{"issue":"12","key":"2019111904555590100_B69","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood-2013-12-544411","article-title":"Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts","volume":"123","author":"Passamonti","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2019111904555590100_B70","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3324\/haematol.2016.143677","article-title":"Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial","volume":"101","author":"Al-Ali","year":"2016","journal-title":"Haematologica"},{"issue":"12","key":"2019111904555590100_B71","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.3324\/haematol.2016.151449","article-title":"The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies","volume":"101","author":"Gupta","year":"2016","journal-title":"Haematologica"},{"issue":"1","key":"2019111904555590100_B72","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40164-015-0021-2","article-title":"The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis","volume":"4","author":"McMullin","year":"2015","journal-title":"Exp Hematol Oncol"},{"issue":"suppl 1","key":"2019111904555590100_B73","first-page":"255","article-title":"Sotatercept (ACE-011) alone and in combination with ruxolitinib in patients (pts) with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) and anemia [abstract]","volume":"130","author":"Bose","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2019111904555590100_B74","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ajh.24572","article-title":"Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients","volume":"92","author":"Polverelli","year":"2017","journal-title":"Am J Hematol"},{"issue":"5","key":"2019111904555590100_B75","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/23744235.2017.1390248","article-title":"Infectious complications in patients on treatment with ruxolitinib: case report and review of the literature","volume":"50","author":"Dioverti","year":"2017","journal-title":"Infect Dis (Lond)"},{"issue":"4","key":"2019111904555590100_B76","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/leu.2016.283","article-title":"Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations","volume":"31","author":"Marchetti","year":"2017","journal-title":"Leukemia"},{"issue":"4","key":"2019111904555590100_B77","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3324\/haematol.2014.115840","article-title":"Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I","volume":"100","author":"Verstovsek","year":"2015","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2019111904555590100_B78","first-page":"1643","article-title":"JAK2-inhibitor therapy associated lymphomas in myelofibrosis: distinct clinico-pathological features recapitulated in a mouse model [abstract]","volume":"130","author":"Tripolt","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2019111904555590100_B79","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3324\/haematol.2010.033779","article-title":"Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients","volume":"96","author":"Rumi","year":"2011","journal-title":"Haematologica"},{"issue":"25","key":"2019111904555590100_B80","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1182\/blood-2011-04-348755","article-title":"Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study","volume":"118","author":"Frederiksen","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019111904555590100_B81","first-page":"1197","article-title":"A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database","volume":"57","author":"Brunner","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2019111904555590100_B82","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.hoc.2017.04.003","article-title":"Mechanisms of resistance to JAK2 inhibitors in myeloproliferative neoplasms","volume":"31","author":"Meyer","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"issue":"5","key":"2019111904555590100_B83","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/14737167.2017.1366858","article-title":"Cost-effectiveness of kinase inhibitors for hematologic malignancies: a systematic and critical review","volume":"17","author":"Marchetti","year":"2017","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"13","key":"2019111904555590100_B84","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2019111904555590100_B85","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/bjh.12274","article-title":"The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis","volume":"161","author":"Verstovsek","year":"2013","journal-title":"Br J Haematol"},{"issue":"45","key":"2019111904555590100_B86","doi-asserted-by":"crossref","first-page":"79073","DOI":"10.18632\/oncotarget.18674","article-title":"Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis","volume":"8","author":"Palandri","year":"2017","journal-title":"Oncotarget"},{"issue":"10","key":"2019111904555590100_B87","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.6004\/jnccn.2017.0157","article-title":"NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018","volume":"15","author":"Mesa","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"2019111904555590100_B88","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bjh.13379","article-title":"Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial","volume":"170","author":"Mead","year":"2015","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111904555590100_B89","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","article-title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN international working group","volume":"29","author":"Kr\u00f6ger","year":"2015","journal-title":"Leukemia"},{"issue":"21","key":"2019111904555590100_B90","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2014-10-608315","article-title":"Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis","volume":"125","author":"Kr\u00f6ger","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2019111904555590100_B91","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/bmt.2013.173","article-title":"Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib","volume":"49","author":"Jaekel","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2019111904555590100_B92","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/leu.2014.86","article-title":"JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET\/PV myelofibrosis","volume":"28","author":"St\u00fcbig","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"2019111904555590100_B93","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.bbmt.2015.10.005","article-title":"Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to janus kinase 1\/2 inhibitors","volume":"22","author":"Shanavas","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2019111904555590100_B94","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00277-017-3194-4","article-title":"Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"97","author":"Kuykendall","year":"2018","journal-title":"Ann Hematol"},{"issue":"9","key":"2019111904555590100_B95","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2019111904555590100_B96","first-page":"201","article-title":"Characteristics and survival of patients with chronic phase myelofibrosis and elevated blasts (5-9%), and the effect of therapy with JAK2 inhibitor ruxolitinib [abstract]","volume":"130","author":"Masarova","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2019111904555590100_B97","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/blood-2017-04-742288","article-title":"JAK2 inhibitors for myeloproliferative neoplasms: what is next?","volume":"130","author":"Bose","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2019111904555590100_B98","first-page":"4197","article-title":"Case series of potential Wernicke\u2019s encephalopathy in patients treated with fedratinib [abstract]","volume":"130","author":"Harrison","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2019111904555590100_B99","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol"},{"issue":"17","key":"2019111904555590100_B100","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1182\/blood-2017-05-785790","article-title":"Ruxolitinib versus best available therapy for ET intolerant or resistant to hydroxycarbamide in a randomized trial","volume":"130","author":"Harrison","year":"2017","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/22\/2426\/1468145\/blood791491.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/22\/2426\/1468145\/blood791491.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T04:56:45Z","timestamp":1574139405000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/131\/22\/2426\/37063\/The-role-of-JAK2-inhibitors-in-MPNs-7-years-after"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,31]]},"references-count":100,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2018,5,31]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2018-01-791491","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,31]]}}}